Skip to main content

Luminex Value Stock - Dividend - Research Selection


ISIN: US55027E1029, WKN: 936597

Market price date: 27.05.2021
Market price: 36,88 USD

Luminex Fundamental data and company key figures of the share

Annual reports in USD
Key figures 25-02-2021
Cash flow
Net operating cash flow 49.931.000
Capital Expenditures -17.910.000
Free cash flow 32.021.000
Balance sheet
Total Equity 517.711.000
Liabilities & Shareholders equity 825.463.000
Income statement
Net income 15.170.000
Eps (diluted) 0,330
Diluted shares outstanding 46.000.000
Net sales/revenue 417.396.000

Fundamental ratios calculated on: 27-05-2021

Key figures 27-05-2021
Cash flow
P/C 33,91
P/FC 52,98
Balance sheet
Income statement
Div. Yield1,09%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization1.693.260.032,00 USD
IndicesNASDAQ Comp.
Raw Data SourceUS GAAP in Millionen USD
Stock Split

Description of the company

Luminex Corporation (Luminex)develops, manufactures and sells biological testing technologies and products with applications throughout the life sciences and diagnostics industries. The Company´s Multi-Analyte Profiling (xMAP) technology, an open architecture, multiplexing technology, allows simultaneous analysis of up to 500 bioassays from a small sample volume, a single drop of fluid, by reading biological tests on the surface of microscopic polystyrene beads called microspheres. xMAP technology combines this miniaturized liquid array bioassay capability with small lasers, digital signal processors and software. Its xMAP technology is being used within various segments of the life sciences industry, which includes the fields of drug discovery and development, and for clinical diagnostics, genetic analysis, bio-defense, food safety and biomedical research. On June 27, 2011, the Company completed its acquisition of 100% interest of EraGen Biosciences, Inc.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,